NCT00368992View on ClinicalTrials.gov

S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Adenocarcinoma of the LungAdenosquamous Cell Lung CancerBronchoalveolar Cell Lung CancerLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
BIOLOGICAL

cetuximab

Given IV

DRUG

paclitaxel

Given IV

BIOLOGICAL

bevacizumab

Given IV

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00368992 - S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter